egeneron has entered the fast growing radiopharmaceutical field through a new strategic collaboration with Telix, aiming to develop next generation targeted cancer therapies. The agreement focuses on combining Regeneron’s antibody expertise with Telix’s capabilities in radiopharma, a modality that delivers radiation directly to tumour cells.

Under the terms, the companies will jointly develop and commercialise multiple programmes, sharing costs and profits equally. Regeneron will provide an upfront payment and may contribute significant milestone payments as the collaboration progresses. The partnership also includes the development of diagnostic tools to help identify suitable patients and monitor treatment response.

Radiopharmaceuticals are gaining momentum across the industry due to their precision approach in oncology, with strong projected market growth in the coming years. For Regeneron, the move signals a strategic expansion beyond its established biologics portfolio into a promising and competitive area of cancer treatment.

The collaboration reflects a broader industry trend as companies seek to build capabilities in targeted radiation therapies, potentially offering new options for patients with difficult to treat cancers.